Blockchain Registration Transaction Record

Incannex's Sleep Apnea Drug Shows 83% Efficacy in Phase 2 Trial

Incannex Healthcare's IHL-42X achieves up to 83% AHI reduction in Phase 2 sleep apnea trial, with strong safety and patient outcomes. Read about progress and financial updates.

This news matters because obstructive sleep apnea affects millions globally, leading to serious health issues like cardiovascular disease and reduced quality of life. Incannex's IHL-42X, with its high efficacy and strong safety profile, could offer a transformative treatment option, potentially reducing reliance on less effective therapies. For investors, the positive Phase 2 results and strengthened financial position signal a lower-risk opportunity in the biotech sector, while advancements in other pipelines like PSX-001 for anxiety highlight the company's broader impact on mental and physical health markets.